Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma-Reference-Cited by-同舟云学术

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma

Published:2016-11-25 Issue:12 Volume:107 Page:1785-1790
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Maruyama Dai¹,Nagai Hirokazu²,Fukuhara Noriko³,Kitano Toshiyuki⁴,Ishikawa Takayuki⁵,Shibayama Hirohiko⁶,Choi Ilseung⁷,Hatake Kiyohiko⁸,Uchida Toshiki⁹,Nishikori Momoko⁴,Kinoshita Tomohiro¹⁰,Matsuno Yoshihiro¹¹,Nishikawa Tomoaki¹²,Takahara Satoko¹²,Tobinai Kensei¹

Affiliation:

1. Department of Hematology National Cancer Center Hospital TokyoJapan

2. Department of Hematology National Hospital Organization Nagoya Medical Center NagoyaJapan

3. Department of Hematology and Rheumatology Tohoku University Graduate School of Medicine SendaiJapan

4. Department of Hematology and Oncology Kyoto University Graduate School of Medicine KyotoJapan

5. Department of Hematology Kobe City Medical Center General Hospital KobeJapan

6. Department of Hematology and Oncology Osaka University Graduate School of Medicine OsakaJapan

7. Department of Hematology National Hospital Organization Kyushu Cancer Center FukuokaJapan

8. Department of Hematology Oncology The Cancer Institute Hospital of the Japanese Foundation for Cancer Research TokyoJapan

9. Department of Hematology and Oncology Japanese Red Cross Nagoya Daini Hospital NagoyaJapan

10. Department of Hematology and Cell Therapy Aichi Cancer Center Hospital NagoyaJapan

11. Department of Surgical Pathology Hokkaido University Hospital SapporoJapan

12. Janssen Pharmaceutical K.K. Tokyo Japan

Funder

Janssen Pharmaceuticals

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.13076

Reference17 articles.

1. How I treat mantle cell lymphoma

2. The World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entities

3. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion

4. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

5. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance;International Journal of Hematology;2024-01-09

2. A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma;Blood Research;2023-12-31

3. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma;International Journal of Clinical Oncology;2023-12-29

4. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies;Journal of Hematology & Oncology;2022-10-01

5. Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis;DARU Journal of Pharmaceutical Sciences;2022-09-03